In the following video, Motley Fool health-care analyst Max Macaluso takes a question from a Fool reader, who writes, "How do you think the initial sales of Arena Pharmaceuticals' (ARNA) Belviq will be?"
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Ask a Fool: What Will Belviq's Launch Do for Arena?
By Max Macaluso
–
Jun 26, 2013 at 5:35PM
NASDAQ: ARNA
Arena Pharmaceuticals
Could Arena Pharmaceuticals' new obesity drug Belviq be facing headwinds right from the start?
Max Macaluso, Ph.D. and The Motley Fool have no position in any stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Arena Pharmaceuticals
ARNA
VIVUS
VVUS
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
3 Clinical Trials to Watch in the First Half of 2022
Why Arena Pharmaceuticals Stock Skyrocketed 80% Today
Arena Pharmaceuticals, inc (ARNA) Q3 2021 Earnings Call Transcript
Arena Pharmaceuticals, inc (ARNA) Q2 2021 Earnings Call Transcript
Arena Pharmaceuticals Inc (ARNA) Q1 2021 Earnings Call Transcript
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.